Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease
- 7 June 2017
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (1) , 241-244
Abstract
(2018). Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease. Leukemia & Lymphoma: Vol. 59, No. 1, pp. 241-244.Keywords
This publication has 15 references indexed in Scilit:
- Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approachesBritish Journal of Haematology, 2016
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008Blood, 2013
- HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell diseaseBlood, 2012
- Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a patient with sickle Cell AnemiaClinical Medicine Insights: Oncology, 2012
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)Blood, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Malignancy in patients with sickle cell diseaseAmerican Journal of Hematology, 2003
- Malignancies in sickle cell disease patients treated with hydroxyureaBritish Journal of Haematology, 2003
- Acute Leukemia in a Patient with Sickle-Cell Anemia Treated with HydroxyureaAnnals of Internal Medicine, 2000